XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV) to reduce costs and administrative burden. The company will maintain its listings on Nasdaq and Frankfurt. The delisting is expected to eliminate duplicative exchange fees, reduce legal and accounting expenses, and allow management to focus on advancing its XRx-026 gout treatment program. Canadian shareholders will retain full trading access on Nasdaq.